Public Health Emergency - Leading a Nation Prepared
For 15 years, BARDA has used Project BioShield to transform health security. With Project BioShield and our partners, we can decrease the negative health consequences from health security threats and save lives.
Antimicrobial resistance is a growing threat to America’s public health and national security. Without payment reform, the antimicrobials marketplace won't survive. In partnerships with HHS divisions, BARDA is seeking to re-catalyze investment into antimicrobial companies by supporting reimbursement reforms & creating market strengthening initiatives.
The U.S. government reached a milestone in its long-standing efforts to defend the country against potential use of chemical weapons: the first FDA clearance of a product to manage certain blister injuries caused by sulfur mustard, commonly known as mustard gas.
ASPR will collaborate with DTRA and VenatoRx Pharmaceuticals, Inc. to develop a novel antibiotic to treat infections caused by bacteria resistant to currently available agents.
Fifteen years ago, Project BioShield was created to get medical countermeasures across the finish line. Last month Congress, took action to further strengthen Project BioShield as part of PAHPAIA of 2019. BARDA is leveraging new legal authorities, strong partnerships and multi-year funding to spur innovation and strengthen health security.
